Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access ...

When even one tiny section of a person’s genetic code becomes mutated or modified, cells can begin to act out of ...

Vertex's gene-editing therapy for sickle cell disease, Casgevy, has been given the nod for use by the NHS in England after an earlier rejection. The importance of biosimilars only continues to ...

Following a breakthrough 'cure' for sickle cell disease being approved on the NHS, the Mirror sat down with four British ...

CASGEVY became the world's first genome editing therapy to receive marketing authorization, beginning with the United Kingdom ...

ToolGen files patent infringement lawsuit against Vertex Pharma in UK for genome editing therapy CASGEVY: Seoul, South Korea Tuesday, April 22, 2025, 15:00 Hrs [IST] ToolGen, Inc.

Bristol Myers Squibb’s new treatment for schizophrenia didn’t provide additional benefits to patients when given on top of ...

In a shining moment for Uganda and the African scientific community, Dr Matthias Magoola, founder of Dei Biopharma, has been ...

Duke University will award honorary degrees to Dr. Rebecca Buckley ’54, David Robinson II ’64 and Dr. Feng Zhang during its ...

ToolGen commences legal action in UK court over Vertex's genome editing therapy, CASGEVY ®Seeks to expand licensing of its proprietary CRISPR RNP technologySEOUL, South Korea, April 21, 2025 /PRNewswi ...

A federal district court had ruled in favor of HHS, restricting Vertex's ability to provide fertility preservation services to Medicaid patients.

Gene editing company ToolGen “seeks fair licensing agreement” for alleged infringement by rival | High-value sickle cell ...